HER2-low gastric cancer: is the subgroup targetable?
2024 · ESMO Open · 23 citations
https://doi.org/10.1016/j.esmoop.2024.103679
K
Keitaro Shimozaki
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
91
Papers
439
Citations
12
h-index
14
i10-index
Keitaro Shimozaki is an academic researcher from The Cancer Institute Hospital. The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Colorectal Cancer Treatments and Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 12, co-authored 78 publications.
ORCID: 0000-0002-4559-5699Papers by this author
worksA novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
2021 · ESMO Open · 15 citations
https://doi.org/10.1016/j.esmoop.2021.100234
Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice
2025 · ESMO Gastrointestinal Oncology · 10 citations
https://doi.org/10.1016/j.esmogo.2024.100128
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan
2022 · Gastric Cancer · 6 citations
https://doi.org/10.1007/s10120-022-01349-y
Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution?
2025 · ESMO Gastrointestinal Oncology · 3 citations
https://doi.org/10.1016/j.esmogo.2025.100257
The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma
2025 · Scientific Reports · 2 citations
https://doi.org/10.1038/s41598-025-92657-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat